MaxCyte ( (MXCT) ) has shared an announcement.
MaxCyte, Inc. has announced a change in major holdings, with BlackRock, Inc. increasing its voting rights in the company to 7.73%. This adjustment in shareholding reflects BlackRock’s growing interest and influence in MaxCyte, potentially impacting the company’s strategic decisions and market positioning.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on cell-based therapies. The company provides cell-engineering platforms that enable the development of innovative medical treatments, with a market focus on improving therapeutic outcomes.
YTD Price Performance: -25.00%
Average Trading Volume: 40,604
Technical Sentiment Signal: Strong Buy
Current Market Cap: £253.6M
For detailed information about MXCT stock, go to TipRanks’ Stock Analysis page.